Central Pa. UPMC Heart and Vascular Institute are First in U.S. to Evaluate New TAVR Stroke Prevention System

Physicians from the UPMC Heart and Vascular Institute at UPMC Harrisburg are the first structural interventional cardiologists in the U.S. to evaluate the effectiveness and safety of a filtration system to prevent blood clots that would be released during the Transcatheter Aortic Valve Replacement (TAVR) procedure from traveling to the brain and causing a stroke.

TAVR is a minimally invasive, catheter-based procedure to treat aortic valve stenosis. During the procedure, the doctor replaces a defective aortic valve with a biological tissue valve. This minimally invasive surgery allows for faster recovery times, a smaller incision, and a shorter hospital stay compared to traditional open heart surgery. During TAVR, particles may be released into the patient’s blood stream, which can reach the brain and cause a stroke. 

Paul Mahoney, MD, co-director of the structural heart program, is a principal investigator in a groundbreaking trial to evaluate the Emblok™ Embolic Protection System. This embolic filtration system inserted during TAVR is designed to capture and remove embolic debris during TAVR. Dr. Mahoney, the site principal investigator, successfully performed the procedure utilizing the Emblok™ System in October at UPMC Harrisburg. 

This trial exemplifies the UPMC Heart and Vascular Institute team’s efforts to utilize groundbreaking research to advance patient care and outcomes. Dr. Mahoney and the entire team of cardiovascular experts at UPMC Harrisburg are continually recognized for their clinical excellence. Recently, the UPMC Heart and Vascular Institute in Central Pa. achieved the highest rating possible from The Society of Thoracic Surgeons (STS) in 4 out of 5 total categories for patient care and outcomes. This rating places UPMC Heart and Vascular Institute in Central Pa. among the most elite cardiac surgery programs — the top 1% — in the U.S. and Canada. For more information on the UPMC Heart and Vascular Institute in Central Pa., visit UPMC.com/CentralPaHeart

This trial is funded by Innovative Cardiovascular Solutions, LLC (ICS).